Astrazeneca Plc Loss Submission Form

Company: Astrazeneca Plc

Ticker: (NYSE) AZN

-729

Days Left

Lead Plaintiff Deadline: March 29, 2021

1
2
3

See If You Qualify For Monetary Reward

Contact Information

Required Field

Required Field

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to files@ZLK.com

Fill in below.

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

1. I have reviewed a complaint filed in the action.

2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.

3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.

4. My transaction(s) in Astrazeneca Plc which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.

5. Within the last 3 years,



6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?



Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP and agree to serve as a lead plaintiff in an action against Astrazeneca Plc. We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any benefit, but we will never ask you to directly pay any of the costs of this litigation. As our client, you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. You further agree to cooperate in our prosecuting the action, including providing relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case. If the Court does not appoint you as a lead plaintiff or you are not added as a plaintiff to a complaint filed in the action, then this retainer agreement and Levi & Korsinsky, LLP's representation of you will terminate automatically.

Looking for more?

Thank you for completing your submission. If our attorneys find you are a viable candidate for lead plaintiff they will reach out regarding the next steps.

All shareholders who submit will receive updates regarding the case.

Class Period

Begins

21

May 2020

Ends

20

Nov 2020

May 21, 2020 - November 20, 2020

Allegations

(a) initial clinical trials for the Company’s COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca’s clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Astrazeneca purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Astrazeneca during the relevant time frame, you have until March 29, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.